FindMyKOL
Clinical trialNCT03257163Active, not recruitingPhase 2Interventional

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

NCT03257163 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it is active and no longer recruiting. It studies Capecitabine and Pembrolizumab in Epstein-Barr Virus Positive, Gastric Adenocarcinoma and 9 more conditions. The registry lists an enrollment of 40 participants at 4 sites in 1 country. The registry lists a start date of 29 Sept 2017 and a primary completion date of 31 Aug 2026. One of its registered investigators has a FindMyKOL profile.

SponsorRutgers, The State University of New JerseyEnrollment40Epstein-Barr Virus PositiveGastric AdenocarcinomaMismatch Repair Protein DeficiencyStage IB Gastric Cancer AJCC v7Stage II Gastric Cancer AJCC v7Stage IIA Gastric Cancer AJCC v7+5 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03257163
FieldValue
Registry IDNCT03257163
StatusActive not recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorRutgers, The State University of New Jersey
Enrollment40
Registered sites4
Countries1
ConditionsEpstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7 and 5 more conditions
DrugsCapecitabine and Pembrolizumab
Start29 Sept 2017
Primary completion31 Aug 2026
Study completion31 Dec 2026
Last update posted20 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well pembrolizumab works with capecitabine and radiation therapy in treating patients with mismatch repair deficient and Epstein-Barr virus positive gastric cancer. Monoclonal antibodies, such as pembrolizumab may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab, capecitabine and radiation therapy may work better at treating gastric cancer.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site
  • Emory University

    Atlanta

New Jersey, United States2 sites
  • Rwjbarnabas Health - Robert Wood Johnson University Hospital, Hamilton

    Hamilton

  • Rutgers Cancer Institute of New Jersey

    New Brunswick

New York, United States1 site
  • Montefiore Medical Center

    The Bronx

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew Jersey: 2 sitesNJ2ConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03257163

Each answer restates registry values shown on this page.

What is NCT03257163?

NCT03257163 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. It studies Capecitabine and Pembrolizumab in Epstein-Barr Virus Positive, Gastric Adenocarcinoma and 9 more conditions.

Is NCT03257163 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT03257163?

The registry names Salma Jabbour (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.

Where does NCT03257163 run?

The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03257163 study?

The registered drug and biological interventions are Capecitabine and Pembrolizumab.

When is NCT03257163 expected to complete?

The registry lists a primary completion date of 31 Aug 2026 and a study completion date of 31 Dec 2026. The sponsor last updated the record on 20 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.